236 related articles for article (PubMed ID: 29797763)
1. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
2. Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.
Abma E; Stock E; De Spiegelaere W; Van Brantegem L; Vanderperren K; Ni Y; Vynck M; Daminet S; De Clercq K; de Rooster H
Sci Rep; 2019 Jun; 9(1):9262. PubMed ID: 31239493
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4-phosphate and its potential in veterinary oncology: a review.
Abma E; Daminet S; Smets P; Ni Y; de Rooster H
Vet Comp Oncol; 2017 Mar; 15(1):184-193. PubMed ID: 25988493
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
7. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
He X; Li S; Huang H; Li Z; Chen L; Ye S; Huang J; Zhan J; Lin T
Br J Clin Pharmacol; 2011 Jun; 71(6):860-70. PubMed ID: 21276042
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
12. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
13. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Dowlati A; Robertson K; Cooney M; Petros WP; Stratford M; Jesberger J; Rafie N; Overmoyer B; Makkar V; Stambler B; Taylor A; Waas J; Lewin JS; McCrae KR; Remick SC
Cancer Res; 2002 Jun; 62(12):3408-16. PubMed ID: 12067983
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections.
Liu P; Qin Y; Wu L; Yang S; Li N; Wang H; Xu H; Sun K; Zhang S; Han X; Sun Y; Shi Y
Anticancer Drugs; 2014 Apr; 25(4):462-71. PubMed ID: 24500030
[TBL] [Abstract][Full Text] [Related]
16. A dose-escalation study of combretastatin A4-phosphate in healthy dogs.
Abma E; Smets P; Daminet S; Cornelis I; De Clercq K; Ni Y; Vlerick L; de Rooster H
Vet Comp Oncol; 2018 Mar; 16(1):E16-E22. PubMed ID: 28620942
[TBL] [Abstract][Full Text] [Related]
17. Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology.
Yin T; Liu Y; Peeters R; Feng Y; Yu J; Himmelreich U; Oyen R; Ni Y
Br J Cancer; 2017 Nov; 117(10):1529-1536. PubMed ID: 28910821
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Nathan P; Zweifel M; Padhani AR; Koh DM; Ng M; Collins DJ; Harris A; Carden C; Smythe J; Fisher N; Taylor NJ; Stirling JJ; Lu SP; Leach MO; Rustin GJ; Judson I
Clin Cancer Res; 2012 Jun; 18(12):3428-39. PubMed ID: 22645052
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
